<DOC>
	<DOCNO>NCT00076180</DOCNO>
	<brief_summary>This study examine use humanize Mik-beta-1 ( Hu-Mik-beta1 ) antibody patient T-cell large granular lymphocytic leukemia ( T-LGL ) . Patients T-LGL often reduce white blood cell , red blood cell , platelet , increase number abnormal cell call large granular lymphocyte ( LGLs ) . Patients may recurrent infection , anemia , abnormal bleeding . Hu-Mik-beta1 attache LGL cell block action growth factor call interleukin stimulate LGL growth . Blocking interleukin may stop T-LGL leukemia cell grow . This study determine dose frequency treatment Hu-Mik- ( SqrRoot ) 1 safely give patient coat surface leukemic cell antibody , determine long antibody last blood injection , examine side effect possible benefit drug patient . Patients age 18 old T-LGL may eligible study . Candidates screen medical history physical examination , review pathology study , skin biopsy , evaluation rheumatoid arthritis present , chest x-ray , computerize tomography ( CT ) scan image study need , bone marrow biopsy , blood urine test . Participants receive single dose Hu-Mik-beta1 90-minute infusion vein . Groups patient treat increase dos ( 0.5 , 1.0 , 1.5 mg/kg ) antibody . Patients develop serious drug side effect take study . The treatment require 3- 4-day hospital stay . In addition Hu-Mik- ( SqrRoot ) 1 treatment , patient undergo follow test procedure : - Collection blood 8 day follow dose Hu-Mik-beta1 measure blood level antibody . - Follow-up visit 1 2 day 22 , 29 , 43 day dose antibody every 3 month total 9 month . - Bone marrow aspirate biopsy one do within 6 week enter study , repeat biopsy complete remission T-LGL achieve complete treatment . For biopsy , area hip numb special needle use draw bone marrow hipbone . - Imaging study , chest x-ray CT scan body complete treatment screen scan show abnormality due T-LGL leukemia . - Lymph node biopsy individual enlarge superficial lymph node due T-LGL leukemia see treatment reach leukemia lymph node . There may may direct benefit participate study . However , result may help treatment future patient .</brief_summary>
	<brief_title>Hu-Mik-beta1 Treat T-Cell Large Granular Lymphocytic Leukemia</brief_title>
	<detailed_description>Background : - T cell large granular lymphocyte ( T-LGL ) leukemia chronic lymphoproliferative disorder associate granulocytopenia , anemia and/or thrombocytopenia . - Although agent cyclosporine methotrexate show activity T-LGL , treatment T-LGL remain largely undefined symptomatic . - The share IL-2R/Il-15R Beta receptor ( CD122 ) express T-LGL cell may stimulate growth T-LGL cell interaction IL-15 . - Hu-Mik-Beta1 humanized monoclonal antibody bind IL-2R/IL-15R Beta - Hu-Mik-Beta1 may inhibit growth exert cytotoxic activity T-LGL cell . Objectives : - To determine dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) Hu-Mik-Beta1 administered patient T-LGL . - To determine dose Hu-Mik-Beta1 required saturate IL-2R/IL-15R Beta ( CD122 ) -T-LGL cell peripheral blood . - To determine pharmacokinetics serum die-away curve Hu-Mik-Beta1 . - To provide preliminary information clinical response follow single dose administration Hu-MiK-Beta1 patient CD122 express T-LGL leukemia . Eligibility : -- T cell large granular lymphocyte leukemia ( T-LGL ) . Patients must granulocyte count less 1000/microL , hemoglobin le 10 gm/dL , transfusion dependent , platelets less 100,000/ microL , combination unless receive hematopoietic growth factor . - T-LGL cell count great equal 1000/microL ( CD3 plus/CD8 plus/usually CD57 plus ) flow cytometry . - Patients may receive stable dose hematopoietic growth factor . Design : - Cohorts 3 patient treat single intravenous dose Hu-Mik-Beta1 0.5 , 1.0 1.5 mg/kg . - Patients observed adverse event 6-weeks . - Detailed pharmacokinetic study determination CD122 receptor saturation perform . - Response evaluate use hematological , flow cytometry , molecular clinical evaluation . - An additional 3 patient accrue high dose MTD aid design Phase II trial . - Patients participate Phase I also eligible participate Phase II .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<criteria>INCLUSION CRITERIA All patient must histologically cytologically confirm TLGL leukemia define : . A peripheral blood smear bone marrow biopsy/aspirate morphological finding consistent LGL determine Hematopathology section , NIH Clinical Center , Laboratory Pathology , NCI , ; ii . An absolute C3+ , CD8+ , usually CD57+ cell ( TLGL ) count great equal 1000/uL peripheral blood bone marrow measure flow cytometry . iii . At least 50 % CD3+/CD8+ cell must also express CD122 ( IL2/15RB plus ) . iv . Clonal T cell receptor ( TcR ) rearrangement desirable , requirement eligibility . TcR rearrangement may determine Southern blot polymerase chain reaction ( PCR ) . Patients must TLGLassociated hemocytopenia ( ) * define absolute granulocyte count ( AGC ) less 1000/uL , platelet count less than100,000/uL hemoglobin le 9.0 gm/dL , require transfusion 3 unit red blood cell product last 6 month , combination . *Patients treat stable dose hemopoietic growth factor great 4weeks whose peripheral blood count exceed value eligible study . A stable dose hematopoeitic growth factor ( ) may continue patient study . Patients require antibiotic treatment antiviral drug two occasion previous 12 month bacterial viral infection associate LGL eligible . Patients must great equal 18 year age . Untreated patient well previously treat cyclosporine A ( CsA ) , chemotherapy , corticosteroid , interferon , erythropoietin , IL11 , GCSF GMCSF , murine MiKBeta1 ( undergone splenectomy eligible study . Omission cyclosporine A , chemotherapy interferon require least 4 week prior entry onto trial . Patients stable dos ( great 4 week ) commercial erythropoietin , GCSF , GMCSF IL11 product eligible study . Patients receive corticosteroid exclude . Patients receive corticosteroid must stable dose prednisone ( le 25 mg/day ) equivalent dose steroid least 3 week receive MiKB 1 study . Patients must normal renal function ( serum creatinine less equal 1.5 mg/dL ) hepatic function ( bilirubin less equal 2.0 mg/dL , SGOT , SGPT le equal 2.5 fold great upper limit normal ) . Patients must Karnofsky performance status great equal 70 % . Patients must life expectancy great 2 month . Patients must able understand sign Informed Consent Document . EXCLUSION CRITERIA Patients must none following time enrollment : Symptomatic central nervous system ( CNS ) involvement LGL leukemia . Pregnant actively nurse patient ineligible . The effect HuMiKBeta1 develop fetus nursing infant unknown . Female patient childbearing potential tested pregnancy within 72 hour initiate study . Patients CTC grade 4 granulocytopenia anemia . Patients require platelet transfusion precede 12months platelet count less equal 10,000/mm ( 3 ) spontaneous bleed episode . Patients test positive human immunodeficiency virus ( HIV ) human T cell lymphotrophic virus ( HTLVI/II ) ineligible , toxicity may different population . Patients test positive hepatitis B virus surface antigen ( HbsAg ) antibodies hepatitis C virus ineligible HuMiKBeta1 therapy might associate increased viral replication . Patients receive prior therapy murine MiKBeta1 develop human antimouse ( HAMA ) human antihuman ( HAHA ) antibody , experience CTC grade III great toxicity attributable antibody ineligible . Patients prior history Grade III great allergic reaction relate previously administer humanize monoclonal antibody ineligible . Patients serious concurrent medical condition ( e.g. , acute myocardial infarction within 6 month , unstable angina , NYHA Class II/IV congestive heart failure , respiratory insufficiency require oxygen therapy , uncontrolled hypertension , symptomatic cerebrovascular disease stroke within 6 month , receive immunosuppression organ graft , etc . ) may otherwise limit survival eligible . Other malignancy within five year , unless probability recurrence prior malignancy less equal 10 percent 5years . Patient 's curatively treat squamous cell carcinoma basal cell carcinoma skin carcinoma situ uterine cervix ( CIN ) patient history malignant tumor past disease free least five year also eligible study . Patients serious active infection require systemic antiinfective therapy . Any physical psychological condition would preclude drug administration patient compliance protocol opinion investigator may pose additional risk administer study drug patient would permit patient complete study give Informed Consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2, 2017</verification_date>
	<keyword>cytotoxic activity T-LGL cell</keyword>
	<keyword>chronic lymphoproliferative disorder</keyword>
	<keyword>T-LGL Leukemia</keyword>
	<keyword>Natural Killer Cells</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphocytic Leukemia</keyword>
	<keyword>T-LGL</keyword>
</DOC>